Patents Issued in November 2, 2021
  • Modified release formulations and uses thereof
    Patent number: 11160758
    Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: November 2, 2021
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Takumi Asada, Gerald R. Galluppi, Seth Cabot Hopkins, Megumi Maruyama, Siriporn Toongsuwan, Yuki Tsushima
  • Capsule with internal diaphragm for improved bioavailability
    Patent number: 11160759
    Abstract: A multi-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an oil. A two-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an oil, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an ingredient. The ingredient may have increased bioavailability after exposure to the oil. This disclosure also provides particular formulations for use in such a capsule.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: November 2, 2021
    Assignee: COMBOCAP, INC.
    Inventor: Tobias Johan Louw
  • Soft capsule based on starch and a method and device for the production thereof
    Patent number: 11160760
    Abstract: A method for producing starch soft capsules comprises the following steps: preparing a mixture comprising starch, plasticizer and water, wherein more than 50 weight percent of the starch is present in the form of particles of granular starch; shaping the mixture to form a film in a shaping process; solidifying the mixture by increasing the temperature of the mixture during and/or after the shaping process by more than 5° C.; and shaping the film to form a soft capsule. Soft capsules produced by this method have starch particles bonded to one another. A device for performing this method comprises a shaping device to enable shaping of the starch material to form a film, and a heating device to perform a heat treatment to destructure the starch during and/or after the shaping. It comprises a rotary die device.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 2, 2021
    Assignee: INNOGEL AG
    Inventors: Rolf Muller, Federico Innerebner
  • Silica microcapsules and methods of preparing same
    Patent number: 11160761
    Abstract: Disclosed is a microcapsule containing: (i) a microcapsule core having an active material, and (ii) a microcapsule wall formed of a first polymer and second polymer. The first polymer is a sol-gel polymer. The second polymer is gum arabic, purity gum ultra, gelatin, chitosan, xanthan gum, plant gum, carboxymethyl cellulose, sodium carboxymethyl guar gum, or a combination thereof. The weight ratio between the first and second polymer is 1:10 to 10:1. Also disclosed are processes for preparing the microcapsule and uses of the microcapsules in consumer products.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: November 2, 2021
    Assignee: International Flavors & Fragrances Inc.
    Inventors: John Brahms, Ronald Gabbard, Feng Geng, Julie Ann Wieland, Li Xu, Lewis Michael Popplewell
  • Modified release coated capsules
    Patent number: 11160762
    Abstract: The present invention relates to a modified release coated capsule and a process to obtain that capsule.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: November 2, 2021
    Assignee: Tillotts Pharma AG
    Inventors: Roberto Carlos Bravo Gonzaléz, Felipe José Oliveira Varum, Thomas Buser
  • Multifunctional pH responsive drug delivery system and method of use
    Patent number: 11160763
    Abstract: A multi-functional drug composition capable of pH responsive drug release comprising siliceous nanoparticles having three dimensional cage structures type silica with thick pore walls and mesosilicalite, superparamagnetic iron oxide nanoparticles (SPION) and pharmaceutical composition thereof is disclosed. The drug delivery system is useful for targeting a drug to particular diseased tissues such as cancerous tissues.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: November 2, 2021
    Assignee: Imam Abulrahman Bin Faisal University
    Inventors: Balasamy Rabindran Jermy, Vijaya Ravinayagam
  • Drug delivery composition containing silyl polymers
    Patent number: 11160764
    Abstract: The invention relates to a silyl-containing polymer that is used, together with a tackifying resin to form an adhesive composition capable of storing and delivering drugs to the skin of a user. Typically the composition is formed into a patch which shows excellent adhesion to the skin even when drugs and other additives are dissolved into the composition.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: November 2, 2021
    Assignees: Medherant Limited, Bostik SA
    Inventors: David Haddleton, David Goubard, Ciaran O'Driscoll
  • Compositions and methods of treating fungal infections of the nails
    Patent number: 11160765
    Abstract: Compositions and methods for reducing the symptoms of skin conditions associated with the nail and surrounding tissue are provided. A medicated pad for cleaning and treating the nail and surrounding tissue is described, wherein said pad is saturated with a therapeutic composition comprising certain botanicals, an antimicrobial agent, a surfactant, and a moisturizing agent. The skin and nail conditions can include fungal infections of the nails. Kits for treating fungal infections of the nails are likewise described. Optionally, the kit may include a hydrating composition which includes shea butter, aloe, vitamins, arnica, emu oil, urea, and Vitamins C, A, E, and D. A bandage comprising a therapeutic pad instilled with an antifungal agent is also provided.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: November 2, 2021
    Assignee: KBR Incorporated
    Inventor: Kenneth Rehm
  • Peritoneal therapeutic fluid
    Patent number: 11160766
    Abstract: Peritoneal therapeutic fluid comprising one or more of a biocompatibility enhancing agent (BCA) that is selected from the group consisting of a polyphenolic compound, a metabolite of a polyphenolic compound which is obtained by metabolization in the human or animal body, a salt or a glycoside of a polyphenolic compound.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: November 2, 2021
    Assignee: OPTERION HEALTH AG
    Inventor: Guido Grentzmann
  • 4,4?-trans-dihydroxystilbene for use in treating cancer
    Patent number: 11160767
    Abstract: The present disclosure provides methods, pharmaceutical compositions, dosing regimens, and kits comprising 4,4?-trans-dihydroxystilbene (DHS), including methods of treating cancer in a subject and methods of decreasing or reversing resistance to a DNA damaging agent in a subject.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: November 2, 2021
    Assignee: The George Washington University, a Congressionally Chartered Not-For-Profit Corporation
    Inventors: Chi-Wei Chen, Yongming Li, Zhiyong Han, Wenge Zhu
  • Paraffin wax with CBD isolate
    Patent number: 11160768
    Abstract: The method comprising melting a composition of matter comprising paraffin wax, mineral oil, aloe vera and CBD, placing a body member into said melted composition several times, withdrawing the body member from said composition, allowing the composition to solidify on the body member and peeling the solidified composition from said body member, said composition being solid, non-tacky, non-sticky and essentially non-material depositing at room temperature.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: November 2, 2021
    Inventor: Edmund M. Dunn
  • Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists
    Patent number: 11160769
    Abstract: This invention relates to pharmaceutical compositions and methods for treating (including managing) or preventing metabolic syndrome related conditions using one or more RAR e.g., RAR agonists. Such conditions include, but are not limited to, diseases in pancreas, liver, kidney, testes, muscle, or adipose tissue, as well as other organs that are associated with high fat diet and/or vitamin A deficiency, as well as other conditions associated with abnormal level of triglyceride, cholesterol and/or glucose.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: November 2, 2021
    Assignee: Cornell University
    Inventors: Lorraine J Gudas, Yannick Benoit, Ronald Perez, Xiao-Han Tang, Steven Trasino
  • Compounds, compositions and methods for treating oxidative DNA damage disorders
    Patent number: 11160770
    Abstract: Compounds, compositions, and formulations, and accompanying methods useful for treating disorders arising from oxidative DNA damage, including oxidative DNA damage resulting from ionizing radiation or other therapy are described herein.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: November 2, 2021
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Mark R. Kelley, Michael R. Vasko
  • Enhanced delivery epinephrine compositions
    Patent number: 11160771
    Abstract: Pharmaceutical compositions having enhanced active component permeation properties are described.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: November 2, 2021
    Assignee: AQUESTIVE THERAPEUTICS, INC.
    Inventors: Alexander Mark Schobel, Stephanie Marie Varjan, Stephen Paul Wargacki
  • Oral amphetamine composition
    Patent number: 11160772
    Abstract: In various embodiments, the present invention is directed to oral pharmaceutical compositions. For example, in some embodiments, the present invention is directed to taste-masked compositions. In some embodiments, the taste masked compositions comprise a highly water soluble drug such as amphetamine, e.g., in the form of a salt such as amphetamine sulfate. In various embodiments, the present invention is directed to taste-masked, orally disintegrating compositions.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: November 2, 2021
    Assignee: ADARE PHARMACEUTICALS, INC.
    Inventors: Gopi M. Venkatesh, Michelle Schilling
  • Method for enhancing folding and transport of misfolded glucocerebrosidase
    Patent number: 11160773
    Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: November 2, 2021
    Assignees: The Hospital for Sick Children, McMaster University
    Inventors: Don J. Mahuran, Michael B. Tropak, Justin D. Buttner, Jan E. Blanchard, Eric D. Brown
  • Energy drinks and other nutritional aids derived from agave-based spirits
    Patent number: 11160774
    Abstract: Compositions containing monoamine oxidase inhibitors prepared by removal of alcohol from agave-derived beverages are disclosed.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: November 2, 2021
    Assignee: Roar Holding LLC
    Inventor: Robert W. Brocia
  • Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
    Patent number: 11160775
    Abstract: Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1? in the wound.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: November 2, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Geoffrey C. Gurtner, Jayakumar Rajadas, Michael Gabriel Galvez, Evgenios Neofytou
  • Compositions and methods for neuroprotection and treatment of neurodegeneration
    Patent number: 11160776
    Abstract: Compositions for neuroprotection and treatment of neurodegeneration and methods of administering same. In particular, the present invention relates to compositions and methods for preventing or reducing neurodegeneration, such as neurodegeneration caused by Huntington's disease, including administering a daily dose of a composition including an effective amount of creatine hydrochloride to a patient in need thereof. The methods of the present invention allow for lower dosages of supplementation as compared to creatine monohydrate while retaining all of the desired biological effects of creatine supplementation.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: November 2, 2021
    Assignee: Vireo Systems, Inc.
    Inventors: Mark C. Faulkner, Donald W. Miller, Grant M. Hatch
  • Omega-3 compositions, dosage forms, and methods of use
    Patent number: 11160777
    Abstract: Omega-3 compositions, dosage forms, and methods of use are disclosed herein. The omega-3 compositions and dosage forms disclosed herein may comprise DHA and EPA. The omega-3 compositions and dosage forms disclosed herein may comprise re-esterified triglycerides. Methods of treatment using the compositions and dosage forms are also disclosed.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: November 2, 2021
    Assignee: Marine Ingredients, LLC
    Inventors: Olav Sandnes, Bruce A. Miller, Jorn Dyerberg
  • Composition for use in the prevention and/or treatment of oncologic treatment induced orogastrointestinal mucositis
    Patent number: 11160778
    Abstract: The present invention refers to a composition for use in the prevention and/or treatment of orogastrointestinal mucositis induced by oncologic treatments. It also refers to the use of said composition for preparing a medicament for the prevention and/or treatment of said orogastrointestinal mucositis. Furthermore, it refers to a method of preventing and/or treating of said orogastrointestinal mucositis in which said composition is administered to a subject in need thereof.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: November 2, 2021
    Assignee: MUCOSA INNOVATIONS, S.L.
    Inventor: Deborah Rodriguez Vilaboa
  • Methods of providing solriamfetol therapy to subjects with impaired renal function
    Patent number: 11160779
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: November 2, 2021
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Katayoun Zomorodi
  • Pharmaceutical composition of ivermectin and process for preparation thereof
    Patent number: 11160780
    Abstract: The invention relates to a topical pharmaceutical composition comprising effective amount of ivermectin as an active agent, process of preparation thereof and method of treating dermatological conditions such as inflammatory lesions of rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acne form rashes, and the like.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: November 2, 2021
    Assignee: Aurobindo Pharma Ltd.
    Inventors: Biswajit Saha, Nilendu Sen, Sivakumaran Meenakshisunderam
  • Apparatuses, methods, and systems for extraction, isolation and conversion of various cannabinoids, and modifications of whole-plant hemp extracts therewith
    Patent number: 11160781
    Abstract: Apparatuses, methods, and systems for extraction, isolation, purification, and conversion of various cannabinoids, and modifications of whole-plant hemp extracts therewith are presented. A method for preparing a whole-plant hemp extract based product includes extracting cannabinoids from plant materials, such as one or more hemp varieties of Cannabis sativa. The method also includes separating and purifying CBD from the extracted cannabinoids, converting purified CBD to ?9-THC and ?8-THC and concurrently converting ?9-THC to CBN, purifying and separating the CBN, and combining the purified CBN with a whole-plan hemp extract. Products and supplements related to the method are also described.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: November 2, 2021
    Assignee: Charlotte's Web, Inc.
    Inventors: Alexander Michael McCorkle, Graham Taylor Carlson, Shelby Renee Sheahan
  • Method for producing nobiletin-containing solid dispersion
    Patent number: 11160782
    Abstract: A nobiletin composition having high water solubility and a method for easily producing the same are provided. A method for producing a solid dispersion comprising nobiletin, comprising the step of mixing nobiletin or a nobiletin-containing product with a water-soluble hesperidin derivative, and then melting the mixture by heating; and the step of solidifying the melted product by cooling. A nobiletin-containing composition produced by the method.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: November 2, 2021
    Assignee: KAO CORPORATION
    Inventors: Masazumi Iwashita, Masahiro Umehara, Shintaro Onishi, Masaki Yamamoto, Keisuke Yamagami, Takaaki Ishigami
  • Multikinase inhibitors for use in the treatment of cancer
    Patent number: 11160783
    Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: November 2, 2021
    Assignee: Eisai R&D Management Co., LTD.
    Inventors: Sergei Agoulnik, Bruce Decosta, Hong Du, Yimin Jiang, Xiang-Yi Li, Kenichi Nomoto, John (Yuan) Wang, Huiming Zhang
  • Treatment of brain metastases using organonitro compound combination therapy
    Patent number: 11160784
    Abstract: The invention provides therapeutic methods and kits for treating brain metastases using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and optionally an additional anti-cancer agent.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: November 2, 2021
    Assignee: EpicentRx, Inc.
    Inventors: Bryan T. Oronsky, Jan Scicinski
  • Methods and compositions for improving cognitive function
    Patent number: 11160785
    Abstract: The invention relates to compositions comprising a synaptic vesicle glycoprotein 2A (SV2A) inhibitor in an extended release and an acetylcholinesterase inhibitor (AChEIs). The invention also relates to using such compositions in treating cognitive impairment associated with central nervous system disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 2, 2021
    Assignee: AgeneBio Inc.
    Inventor: Gardiner Smith
  • Rapid disperse dosage form
    Patent number: 11160786
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: November 2, 2021
    Assignee: APRECIA PHARMACEUTICALS LLC
    Inventors: Jules Jacob, Norman Coyle, Thomas G. West, Donald C. Monkhouse, Henry L. Surprenant, Nemichand B. Jain
  • 4-(4-chlorophenyl)-5-methylene-pyrrol-2-one and 5-methylene-4-(p-tolyl)pyrrol-2-one for use in the treatment of gram negative bacterial infections
    Patent number: 11160787
    Abstract: 4-(4-Chlorophenyl)-5-methylene-pyrrol-2-one and 5-methylene-4-(p-tolyl)pyrrol-2-one for use in the treatment of gram-negative bacterial infections, in particular infections in which Pseudomonas is implicated.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: November 2, 2021
    Assignee: Conopco, Inc.
    Inventors: Neil James Parry, Paolo Pantalone, Paul Williams
  • Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
    Patent number: 11160788
    Abstract: Described herein are methods for preventing, delaying the onset or reducing the severity of, preventing or reversing the progression of, or treating a neurological condition (e.g., a neurodegenerative disease (e.g., Alzheimer's disease)) in a subject, based on caspase-1 inhibition. Also described herein are methods for preventing, delaying the onset or reducing the severity of, preventing or reversing the progression of, or treating cognitive impairment in a subject, based on caspase-1 inhibition. Corresponding uses and kits are also described. In an embodiment, the caspase-1 inhibitor is VX-765 or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 2, 2021
    Inventor: Andrea Leblanc
  • Compounds for the treatment of cancers associated with human papillomavirus
    Patent number: 11160789
    Abstract: The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus. The present invention also relates to the pharmaceutical compositions containing the compounds of Formula (I) for the treatment of cancers associated with human papillomavirus.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: November 2, 2021
    Assignee: PIRAMAL ENTERPRISES LIMITED
    Inventors: Swati Ajay Piramal, Muralidhara Padigaru, Veena R. Agarwal, Gandhali Ashwin Deshpande
  • Method of inhibiting growth using eltrombopag
    Patent number: 11160790
    Abstract: Provided is a method of inhibiting the growth of a fungus using eltrombopag, wherein the fungus is selected from the group consisting of Cryptococcus, Candida glabrata, and Trichophyton rubrum. Also provided are a combination agent that includes eltrombopag and a macrolide calcineurin inhibitor and a method of using the combination agent for inhibiting the growth of Cryptococcus. Also provided is a method of inhibiting virulence factor formation in Cryptococcus using eltrombopag.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: November 2, 2021
    Assignee: NATIONAL TAIWAN UNIVERSITY
    Inventors: Ying-Lien Chen, Hao-Tai Ko, Li-Hang Hsu, Sheng-Yung Yang
  • Dexmedetomidine injection premix formulation in ready to use (RTU) bags
    Patent number: 11160791
    Abstract: The application provides pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof and sodium chloride, wherein the composition is disposed within a plastic container as a ready to use premixture. The application also provides a premixed, ready to use sterile dexmedetomidine solution comprising dexmedetomidine and sodium chloride, wherein the solution is provided within a plastic container. Also provided are methods of providing dexmedetomidine to a subject in need of such, wherein the composition is disposed within a sealed plastic container.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: November 2, 2021
    Assignee: Medefil, Inc.
    Inventors: Lakshmi Prasanna Kolluru, Zhiwen Guan, Sunil Potdar, Ravinder Malhotra, Pradeep Aggarwal
  • Opioid receptor modulator dosage formulations
    Patent number: 11160792
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: November 2, 2021
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Solid dosage forms of bendamustine
    Patent number: 11160793
    Abstract: In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable or oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: November 2, 2021
    Assignee: Astellas Deutschland GmbH
    Inventors: Jeffrey Colledge, Thomas Alfred Profitlich, Ulrich Patzak, Taoufik Ouatas, Margaretha Olthoff
  • Methods for treating congenital disorders of glycosylation
    Patent number: 11160794
    Abstract: The present disclosure relates generally to compounds and pharmaceutical compositions for increasing glycosylation and treating congenital disorders of glycosylation.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: November 2, 2021
    Assignee: Maggie's Pearl, LLC
    Inventors: Ethan Oren Perlstein, Jessica Lao, Feba Sam, Nina DiPrimio, Zachary Parton, Hillary Tsang, Kausalya Murthy, Sangeetha Venkatraman Iyer, Joshua Mast, Tamy May Sharly Portillo Rodriguez, Madeleine Prangley
  • Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
    Patent number: 11160795
    Abstract: The present disclosure provides methods of treating tuberous sclerosis complex comprising administering cannabidiol and everolimus.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: November 2, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Volker Knappertz, Eduardo Dunayevich, David Critchley
  • Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
    Patent number: 11160796
    Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: November 2, 2021
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Arturo Molina
  • Pyridinone derivatives and their use as selective ALK-2 inhibitors
    Patent number: 11160797
    Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: November 2, 2021
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Sylvie Chamoin, Pier Luca D'Alessandro, Mika Lindvall, Dimitrios Lizos, Nikolaus Johannes Stiefl, Sylvie Teixeira-Fouchard, Thomas Ullrich, Sven Weiler
  • Neuroprotective CB2 receptor agonists
    Patent number: 11160798
    Abstract: A method of treating or preventing a neuroinflammatory and/or neurodegenerative disease in a subject by administering a pharmaceutically effective amount of a CB2 receptor agonist is described. The CB2 receptor agonist can be a compound according to formula I or a pharmaceutically acceptable salt thereof, with R1 and R2 as defined herein. Administration of the CB2 receptor agonist activates CB2 receptors in the microglia, and can restore syntaptic plasticity, cognition, and memory in subjects having elevated levels of amyloid-ßpeptide in the brain.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: November 2, 2021
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Mohamed Naguib Attala, David L. Brown
  • Pediatric combination
    Patent number: 11160799
    Abstract: An aqueous composition for intranasal administration by spray including a mixture of (a) sufentanil, a salt and/or analogs thereof and (b) ketamine, a salt and analogs thereof in solution. Also, an aqueous composition for intranasal administration by spray including (a) sufentanil, a salt and/or analogs thereof in solution and an aqueous composition for intranasal administration by spray including (b) ketamine, a salt and/or analogs thereof in solution, for use in a method for the treatment or prevention of pain in a child. The composition is useful for treating or preventing pain in a child of 17 years or younger. The composition is delivered from a nasal spray device to treat or prevent the pain such as procedural pain in a child.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: November 2, 2021
    Assignee: Cessatech A/S
    Inventors: Steen Henneberg, Bettina Nygaard Nielsen
  • Methods of treatment using a JAK inhibitor compound
    Patent number: 11160800
    Abstract: The invention relates to methods of treating ocular diseases and certain respiratory diseases using the compound 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: November 2, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Venkat R. Thalladi, Hao Zhang
  • RORgamma modulators and uses thereof
    Patent number: 11160801
    Abstract: The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 2, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • Composition and methods for preventing or reducing the incidence of transient ischemic attacks
    Patent number: 11160802
    Abstract: A composition and method for preventing or reducing the incidence of a transient ischemic attack in a subject at risk for developing a stroke comprises orally administering to the subject a prophylactically effective amount of a pharmaceutical composition comprising an ASIC1a inhibitor capable of penetrating the blood-brain barrier. Preferred ASIC1a inhibitors for use in the disclosed methods include amiloride and amiloride analogs.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: November 2, 2021
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Zhigang Xiong, Roger P. Simon
  • Phthalazinone derivatives
    Patent number: 11160803
    Abstract: Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X?NRX then n is 1 or 2 and if X?CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: November 2, 2021
    Assignee: KUDOS PHARMACEUTICALS LIMITED
    Inventors: Niall Morrison Barr Martin, Graeme Cameron Smith, Stephen Philip Jackson, Vincent Junior M Loh, Xiao-Ling Fan Cockcroft, Ian Timothy Williams Matthews, Keith Allan Menear, Frank Kerrigan, Alan Ashworth
  • Pharmaceutical dosage forms
    Patent number: 11160804
    Abstract: The present invention relates to solid pharmaceutical dosage forms comprising the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea or any pharmaceutically acceptable salt thereof. It further relates to processes of making said solid pharmaceutical dosage forms.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: November 2, 2021
    Assignee: Novartis AG
    Inventor: Suzie Jesus Ribeiro
  • Kinase inhibitor salts and compositions thereof
    Patent number: 11160805
    Abstract: The present invention relates to kinase inhibitor C8-C16 aliphatic sulfate salts, compositions containing kinase inhibitor C8-C16 aliphatic sulfate salts and uses thereof.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: November 2, 2021
    Assignee: HANDA ONOCOLOGY, LLC
    Inventors: Fang-Yu Liu, K. C. Sung, Chin-Yao Yang, Chi-Cheng Lin, Yi-Hsin Lin, Li Qiao
  • Salt of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino) piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation, and formulations containing it
    Patent number: 11160806
    Abstract: New N-(2,6-diethylphenyl)-8-({4-[4-(dimethyl amino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II): Medicaments.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: November 2, 2021
    Assignee: NERVIANO MEDICAL SCIENCES S.r.l.
    Inventors: Massimo Zampieri, Marina Caldarelli, Ilaria Candiani, Matteo D'Anello, Germano D'Arasmo
  • Methods, compositions and devices for treating cancer with illudofulvenes
    Patent number: 11160807
    Abstract: In an embodiment of the invention, a method of treating cancer includes screening to select a patient population that will respond to an Illudofulvene Analog composition based on the presence of one or more Transcription Coupled Repair (TCR) mutations, deletions or other events interfering with TCR biomarker expression in combination with upregulation of Myc and/or PTGR biomarker expression and treating the patient population with the Illudofulvene Analog composition.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: November 2, 2021
    Assignee: AF Chemicals, LLC
    Inventor: Michael Kelner